Compare Abeona Therapeutics Inc (ABEO) vs KeyCorp (KEY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs KeyCorp — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while KeyCorp trades at $22.64 (market cap $25.22B). The key difference: KeyCorp is far larger — about 67.6× Abeona Therapeutics Inc's market cap, and KeyCorp pays a 3.51% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KEY | |
|---|---|---|
Market Cap | $373.32M | $25.22B |
Sector | Health | Financials |
52-Week High | $7.23 | $23.43 |
52-Week Low | $4.17 | $16.78 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
KeyCorp (KEY) trades at $23.37, up 1.52% today, with a bullish technical signal and strong earnings momentum after three consecutive quarterly beats. The stock shows robust fundamentals with a P/E of 14.37, net income margin of 26.05%, and a new $3 billion buyback program. Recent news highlights its inclusion in dividend-focused strategies and potential for further earnings outperformance.
Outlook remains positive given analyst consensus of $29.55 price target and 60.79% buy ratings. Risks include volatile cash flows and banking sector sensitivity to interest rates, but capital returns and earnings growth support upside potential for investors seeking value and income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
